Cronos Group Inc (CRON) Receives C$21.25 Consensus PT from Analysts
Cronos Group Inc (TSE:CRON) has received a consensus rating of “Hold” from the eight ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and two have assigned a hold rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is C$21.25.
Several brokerages have weighed in on CRON. Jefferies Financial Group decreased their price objective on shares of Cronos Group from C$17.00 to C$15.00 in a research note on Friday, May 3rd. Canaccord Genuity decreased their price objective on shares of Cronos Group from C$17.00 to C$16.00 in a research note on Friday, May 10th. CIBC decreased their price objective on shares of Cronos Group from C$30.00 to C$25.00 in a research note on Friday, May 10th. Bank of America reaffirmed an “underperform” rating and set a C$17.00 price objective on shares of Cronos Group in a research note on Wednesday, April 17th. Finally, Cormark upped their price objective on shares of Cronos Group from C$17.00 to C$25.00 in a research note on Thursday, March 28th.
TSE CRON traded down C$0.43 on Friday, reaching C$20.07. The company’s stock had a trading volume of 598,295 shares, compared to its average volume of 2,277,714. The stock has a market cap of $6.89 billion and a P/E ratio of 36.08. Cronos Group has a 52 week low of C$7.33 and a 52 week high of C$32.95. The company has a quick ratio of 1.42, a current ratio of 1.44 and a debt-to-equity ratio of 0.25.
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada.
Featured Article: What is an overbought condition?
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.